Telix Pharmaceuticals (ASX:TLX), an Australian-based biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or 'molecularly-targeted radiation' (MTR), has announced creation of its Japanese subsidiary and appointment of the first two members of the its leadership team.
Telix Japan is a wholly-owned operating subsidiary of Telix Pharmaceuticals Limited.
According to the company, the purpose of the subsidiary is to support its Japanese clinical and radiopharmaceutical manufacturing activities and establish a commercial footprint in the county.
Dr Shintaro Nishimura has been appointed president and chief operating officer. Dr Takeshi Oka has been appointed chief medical officer.
Telix co-founder and CEO, Dr Christian Behrenbruch, said, “Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies. The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-calibre executives to lead our development and commercial activity.”
“Telix has an exciting commercial opportunity for its products in Japan and Dr Oka and I are pleased to be leading the Company’s activities in the Japanese market," said Dr Nishimura. "There is considerable interest in Telix’s oncology pipeline from our top nuclear medicine clinics and we hope to use this interest to obtain the additional data required to meet the marketing authorization requirements of the Pharmaceuticals and Medical Devices Agency (PMDA) to make Telix’s technology available to Japanese cancer patients.”